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pH 7.4). However, at pH < 7 the t1/2 of Ga(CyAAZTA)¯ is much longer (234h at pH 6).
Finally, CyAAZTA was successfully radiolabelled with ⁶⁸Ga in acetate buffer at pH 3.8,
15 min reaction at room temperature and [CyAAZTA]=10 μM, with a labelling yield
higher than 80%. 1 μM solution of CyAAZTA was successfully labelled (L.Y.: 97.4%) in
5 min at 90°C. Stability tests in human serum and in the presence of 50 mM DTPA
showed that ⁶⁸GaCyAAZTA was highly stable over 90 min.
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and ligand exchange kinetics of the Ga(III) complex. The optimization of the ⁶⁸Ga
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A rigidified AAZTA-like ligand as efficient chelator for 68Ga 
radiopharmaceuticals 
Adrienn Vágner,[a] Calogero D’Alessandria,[b] Giuseppe Gambino,[c] Markus Schwaiger,[b] Silvio Aime,[d] 
Alessandro Maiocchi,[e] Imre Toth,[a] Zsolt Baranyai,*[a] Lorenzo Tei*[b,c] 
Abstract: The new cyclohexane fused CyAAZTA ligand was 
synthesized to increase the structural rigidity of the heptadentate 
chelator AAZTA with the aim to improve the overall stability of its 
GaIII complex. The stability constant of Ga(CyAAZTA)-, determined 
both by pH-potentiometry (logKGaL = 21.39) and by 
71Ga NMR 
(logKGaL = 21.92), was found similar to that of GaAAZTA (logKGaL = 
22.18). The kinetic inertness of Ga(CyAAZTA)- was investigated by 
following its transmetallation and ligand exchange reactions with 
Cu2+ and human serum transferrin, respectively. The formation of a 
hydroxo-complex near pH 7 decreases the half-life (t1/2) of the 
dissociation reactions for Ga(CyAAZTA)- with respect to Ga(AAZTA)- 
(8.5 h vs 21 h, pH 7.4). However, at pH < 7 the t1/2 of Ga(CyAAZTA)
- 
is much longer (234h at pH 6). Finally, CyAAZTA was successfully 
radiolabelled with 68Ga in acetate buffer at pH 3.8, 15 min reaction at 
room temperature and [CyAAZTA]=10 M, with a labelling yield 
higher than 80%. 1 M solution of CyAAZTA was successfully 
labelled (L.Y.: 97.4%) in 5 min at 90°C. Stability tests in human 
serum and in the presence of 50 mM DTPA showed that 
68GaCyAAZTA was highly stable over 90 min. 
Introduction 
The widespread clinical application of 68Ge-based radioisotope 
generators (t½ (68Ge)=270.8 days) for the production of the PET 
isotope 68Ga (t½ = 67.71 min, E+,max=1.89 MeV, 89% decays 
through positron emission), together with the favorable 
properties of such isotope, i.e. half-life sufficient for production 
and application of tracers by minimizing the radiation dose to the 
patient, has boosted the research activity with the aim of 
designing  effective, specific and safe 68Ga-based 
radiopharmaceuticals.1,2 The established diagnostic power of the 
PET technique coupled to the increasing availability of new 
receptor specific peptides and high affinity proteins have led to 
the design and testing of a large number of 68Ga-based 
radiopharmaceuticals in oncology, cardiology, neurology, and 
infection diseases.3 These tracers allow a personalized medical 
approach with accurate quantitative diagnosis and staging for 
subsequent selection and planning of therapeutic methods.4 In 
this context, a prostate-specific membrane antigen (PSMA) 
inhibitor for imaging and therapy for 68Ga-based PET and 177Lu-
based endoradiotherapeutic treatment in patients with metastatic 
and castration-resistant disease is currently under intense 
scrutiny.5 
A 68Ga-based radiopharmaceutical consists of a 
thermodynamically stable and kinetically inert GaIII complex 
linked to a specific vector, most often represented by peptides or 
pseudo-peptides. Ga3+ ions should be complexed, typically at 
acidic pH to avoid the formation of Ga(OH)3, by a chelator 
having at least 6 donor atoms (N- or O-donors) that is able to 
wrap around the metal ion and prevent the transmetallation 
reaction with endogeneous metal ions (Cu2+, Zn2+, Ca2+) or 
ligand exchange reactions with proteins such as transferrin. It is 
well established that macrocyclic chelators such as 1,4,7,10-
tetraazacyclododecane tetraacetic acid (DOTA) and 1,4,7-
triazacyclononane-1,4,7-triacetic acid (NOTA), either free or 
conjugated to peptides, form very stable complexes with 68Ga.6 
Recently, it has been reported that a NOTA-phosphinate analog 
(TRAP, Tri-Azacyclononane-tri-Phosphinic acid) and its 
conjugated multimeric systems show an enhanced efficacy in 
forming stable 68Ga-complexes at ambient temperature, very low 
pH (<1) and low chelator concentrations.7 It is straightforward to 
note that an efficient 68Ga-labeling reaction, without the need to 
work at high temperatures (i.e. 95°C as for DOTA-based 
systems) represents a very attractive opportunity when 
producing fragile temperature sensitive macromolecular tracers.8 
In this context, a polyaminopolycarboxylate heptadentate ligand 
based on a 1,4-diazepine scaffold (AAZTA = 6-amino-6-
methylperhydro-1,4-diazepinetetraacetic acid, Scheme 1) has 
been thoroughly studied as chelator for Gd3+ ions for Magnetic 
Resonance Imaging applications.9 This ligand has already been 
proved to form thermodynamically stable and kinetically inert 
GaIII complexes10 and an AAZTA-RGD peptide conjugate have 
been recently shown to complex 68Ga at room temperature, in 
acetate buffer at pH 3.8.11 Moreover, Parker and co-workers 
carried out the 68Ga-labelling with a series of hexadentate 
diazepine-based chelators similar to AAZTA synthesized by 
removing one carboxylate arm on the hexocyclic amine (AAZ3A, 
Scheme 1).12 They reported that, whereas 68GaAAZTA was 
efficiently formed as a mixture of three isomers, the AAZ3A-
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based ligands can bind 68Ga rapidly and selectively in acetate 
buffer at pH 4 to 7, forming kinetically stable complexes.  
 
Scheme 1. 1,4-diazepine-based polyaminopolycarboxylate ligands for Ga(III) 
complexation 
With the aim to improve further the performance of the AAZTA 
chelator, we designed a new ligand having a cyclohexane ring 
fused on the seven-membered diazepine ring to enhance its 
structural rigidity. It is known that the structural stiffening of the 
ethylenediaminetetraacetic acid (EDTA) backbone induced by 
the substitution of the 1,2-diaminoethane moiety by the trans-
1,2-diaminocyclohexyl group (Cyclohexyl-DTA - CDTA) results in 
the increase of the thermodynamic stability and kinetic inertness 
of the metal complexes formed by these ligands.13 Therefore, to 
establish the effect of the presence of trans-1,2-
diaminocyclohexyl moiety on the coordination ability of the 
AAZTA skeleton, herein we report the synthesis of trans-3-
amino-3-methyldecahydro-1H-1,5-benzodiazepine-N,N',N",N" 
tetraacetic acid (CyAAZTA, Scheme 1) and a full account of the 
solution thermodynamics of its GaIII complex, along with a 
detailed kinetic study of the principal dissociation pathways. The 
68Ga labelling of CyAAZTA was also carefully tested in order to 
find the best conditions for an efficient labelling. 
Results and Discussion 
Synthesis. The synthesis of CyAAZTA is analogous to that 
reported for the parent AAZTA ligand.9a (±) trans-1,2-
dibenzylaminocyclohexane (1), prepared by reductive amination 
of (±) trans-1,2-diaminocyclohexane with benzaldehyde, was 
used in place of N,N’-dibenzylethylenediamine in the key 
cyclization step.  The formation of the seven-membered ring was 
achieved through the high-performing double nitro-Mannich 
reaction with 1, nitroethane and paraformaldehyde (Scheme 2). 
Reduction of the nitro group and combined hydrogenolysis of the 
N-benzyl groups was achieved by Pd/C catalysed hydrogenation. 
The triamine was then alkylated by reaction with tert-butyl 
bromoacetate in acetonitrile in the presence of K2CO3 as base. 
Finally, the tert-butyl esters were removed in a 1:1 mixture of 
TFA and dichloromethane to obtain the desired ligand.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 2. Synthesis of CyAAZTA. 
 
Solution equilibrium studies.  
Protonation equilibria: The protonation constants of CyAAZTA 
(logKiH, i = 1, 2…5), defined by Equation (1), were determined by 
pH-potentiometry (Figure S1) and are listed in Table 1 where are 
compared with those of AAZTA, EDTA and CDTA. 
 
(1) 
 
 
Table 1. Protonation constants of H4CyAAZTA, H4AAZTA, H4CDTA and 
H4EDTA (0.1 M KCl, 25C) 
 H4CyAAZTA H4AAZTA[a,b] H4CDTA[c] H4EDTA[c] 
logK1H 10.48 (2) 11.23 11.70 10.14 
logK2H 6.43 (2) 6.52 6.12 6.02 
logK3H 4.23 (2) 3.78 3.52 2.53 
logK4H 2.76 (2) 2.24 2.43 1.99 
logK5H 1.68 (2) 1.56   
logKiH 25.58 25.33 23.77 20.69 
[a] Ref. [14], [b] Ref. [10], [c] Ref. [15] 
 
The comparison of protonation constants between CyAAZTA 
and AAZTA (Table 1) indicates that logK1H value for CyAAZTA is 
significantly lower, whereas logK3H for CyAAZTA is nearly half 
order of magnitude higher. The lower logK1H value of CyAAZTA 
might be explained by the presence of the trans-1,2-
diaminocyclohexyl moiety which can distort the 7-membered ring 
resulting in the lower cooperation between the exocyclic- and 
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ring-N donor atoms during the first protonation process as 
shown to happen in case of AAZTA.[10]  This view is supported 
by the similarity of the logK1H values for CyAAZTA (10.48) and 
for 1,4-diazacycloheptane-N,N-diacetic acid (9.83).[16] The 
difference in the logK3H values might be accounted for the higher 
basicity of one carboxylate O-atom due to the electron donation 
of the cyclohexyl ring. An analogous explanation was forwarded 
to explain the logK3H value for CDTA in comparison with EDTA.  
Noteworthy, the total basicity (logKiH) of CyAAZTA is 
comparable with that of AAZTA (Table 1). 
Complexation properties: The stability and protonation constants 
of Ga(CyAAZTA)- and Cu(CyAAZTA)2- are defined by Eqs. (2) 
and (3): 
(2) 
 
 
(3) 
 
 
The stability constants of Ga(CyAAZTA)- (Table 2) were 
determined by pH-potentiometry (Figure S1) following the 
competition between CyAAZTA and OH- ions for Ga3+ (Eq. (4)) 
at high pH values (pH>8) using the hydrolysis constants of the 
free Ga3+ ion (logK[Ga(OH)]2+ = -2.97, logK[Ga(OH)2]+ = -5.92, 
logK[Ga(OH)3]  = -8.2 and logK[Ga(OH)4]- = -16.81).[17-19].  
 
Ga(CyAAZTA) +  nOH-  [Ga(OH)n]3-n +  CyAAZTA  n=3,4  (4) 
 
The protonation constants of Ga(CyAAZTA)- were calculated 
from the titration curves obtained at 1:1 metal to ligand 
concentration ratios by titrating the complex with HCl and NaOH 
solutions, respectively. The titration data of Ga(CyAAZTA)- 
obtained at pH>6 indicate the occurrence of a base consuming 
process. This process can be interpreted by assuming the 
coordination of a OH- ion and the formation of 
[Ga(CyAAZTA)OH]2- according to Eqs. (5) and (6): 
 
M   +   L   +   OH-         ML(OH)-                       (5) 
 
 
 
ML(OH-)   +   H+         ML   +   H2O                   (6) 
 
 
 
The stability constants of Ga(CyAAZTA)- is slightly lower than 
that of Ga(AAZTA)- (Table 2), probably as a result of the higher 
rigidity of the CyAAZTA chelator. Moreover, the formation of 
[Ga(CyAAZTA)OH]- (characterized by the logKGaLH-1 protonation 
constant) starts at pH>6.0, 3 pH units higher that of Ga(AAZTA)- 
takes place. The stability constant of Cu(CyAAZTA)2- (logKCuL = 
20.11 (2)) was determined by spectrophotometry in the [H+] 
range of 0.01 – 1.0 M ([CyAAZTA]=[Cu2+]= 210-3 M) and the 
data are reported in ESI. 
The Ga3+- CyAAZTA equilibrium system was also investigated 
by means of 1H- and 71Ga-NMR spectroscopy. 71Ga- and 1H-
NMR spectra obtained at 1:1 Ga3+ to CyAAZTA ratio in the pH 
range 0.7-12.7 are presented in Figures 1 and S4, respectively. 
71Ga-NMR data were also used for the calculation of the stability 
constants of [Ga(CyAAZTA)OH]2-. The integrals of the 71Ga-
NMR signals ([Ga(OH)4]- at 223 ppm, Fig. 1B) were used for the 
calculation of the logGaLH-1 value of [Ga(CyAAZTA)OH]2-  (Table 
2). 
 
Table 2. Stability and protonation constants of the GaIII-complexes of 
CyAAZTA and AAZTA (0.1 M KCl, 25C) 
 Ga(CyAAZTA) Ga(AAZTA)[a] 
 
pH-pot. 
1H- and 71Ga-
NMR 
pH-pot. 
1H- and 71Ga-
NMR 
logKGaL 21.39 (3) 21.92 (8) 22.18 22.36 
logKGaHL 4.09 (3)  3.05  
logKGaH2L 2.32 (3) + logKGaLH-1 0.82 + logKGaLH-1 
logKGaLH-1 7.31 (3)  4.49  
logGaLH-1 14.08 (3) 14.61 (8) 17.69 17.87 
pGa[b] 22.0 22.4 pGa[b] 22.0 
[a] Ref. [10], [b] pGa=-log[Ga3+]free, [Ga3+]tot=110-8 M, [L]tot=110-7 M, 
pH=7.4. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. 71Ga-NMR spectra (122 MHz) of Ga(CyAAZTA) ([GaL]=0.02 M, 
75°C, pH=5.0, D2O) (A) and Ga3+-CyAAZTA systems ([Ga3+]= [CyAAZTA]= 
0.015 M, 0.1 M KCl,  25°C (B).  
The logGaLH-1 values of [Ga(CyAAZTA)OH]2- obtained by pH-
potentiometry (logGaLH-1 = 14.08 (3)) and NMR spectroscopy 
(logGaLH-1=14.61 (8)) are in good agreement (Table 2). The 
equilibrium data obtained by the pH-potentiometric titration 
combined with the results of NMR studies, allowed to calculate 
the species distribution diagram for the Ga3+-CyAAZTA system 
(Figure 2). The species distribution diagram and 71Ga-NMR 
spectra indicate that the complex formation is complete at 
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pH>1.5. The gallium resonance is relatively sharp for the highly 
symmetric [Ga(H2O)6]3+ species (Fig. 1B, ½ = 51 Hz) at pH0.7. 
The intensity of the 71Ga-NMR signal of the aquaion decreases 
by increasing the pH due to the formation of protonated 
Ga(H2CyAAZTA)+ and Ga(HCyAAZTA) complexes in the pH 
range 0.7 - 1.4. In Ga(AAZTA)-, the Ga3+ ion is coordinated by 3 
amino-N and 3 carboxylate-O donor atoms with a distorted 
octahedral geometry (one of the carboxylate-O donors does not 
coordinate),[10] and presumably the coordination geometry of 
Ga(CyAAZTA)- is similar. In the pH range 1.4 - 5.0, the 
deprotonation of the Ga(H2CyAAZTA)+ and Ga(HCyAAZTA) 
results in a slight upfield shift of all signals in the 1H NMR 
spectrum (Fig. S4) which indicates that these processes take 
place at the weakly- or non-coordinated carboxylate groups of 
the ligand. At pH>6.0 the formation of the [Ga(CyAAZTA)OH]2- 
species become evident by the extra equivalent base 
consumption during the pH-potentiometric titration and the new 
set of signals in the 1H-NMR spectra (Fig. S4). At pH=8, the 
[Ga(CyAAZTA)OH]2- is the predominant species (Fig. 2). The 
OH- ion of [Ga(CyAAZTA)OH]- is coordinated directly to the 
metal ion replacing one carboxylate O-atom. At pH > 8.0, the 
appearance of the 71Ga-NMR signal of the [Ga(OH)4]- (Fig. 1B, 
Ga=223 ppm) and the 1H-NMR signals of the free CyAAZTA 
indicate that CyAAZTA is getting replaced by the OH- ions in the 
competition reaction for Ga3+ ion with the formation of Ga(OH)3 
and [Ga(OH)4]- species. The 1H-NMR signal of the methyl 
protons of the free and the complexed CyAAZTA are well 
separated (H=0.92 and 1.12 ppm, respectively). The intensity 
and the chemical shifts of the methyl protons of complexed and 
free CyAAZTA indicates the dissociation of [Ga(CyAAZTA)OH]2- 
and the deprotonation of free CyAAZTA in the 8.2 – 12.2 pH 
range. 
Figure 2. Species distribution of Ga3+ - CyAAZTA system calculated from the 
pH-potentiometric titration data. The percentage of Ga3+aq (), 
[Ga(CyAAZTA)OH]2- (▲) and [Ga(OH)4]- (■) calculated from the NMR data. 
([Ga3+] = [CyAAZTA] = 15 mM, 0.1 M KCl, 25C). 
At pH=5.0 and 298 K, the 71Ga-NMR signal of Ga(CyAAZTA)- is 
very broad and almost not observable, even broader than that of 
Ga(AAZTA)- (Ga=118 ppm, ½ = 2200 Hz).[10] This is clearly the 
result of the asymmetric coordination environment of the Ga3+ 
ion provided by the rigid CyAAZTA. Generally, the broadening or 
sharpening of the 71Ga-NMR signal could be interpreted either 
by an exchange processes or by the interaction of the nuclear 
quadrupole moment with the electric-field gradient at the 71Ga 
nucleus.[20] In particular, the VT - 71Ga-NMR spectra of 
Ga(CyAAZTA) (Fig. S5-B) show a sharpening of the linewidth 
with increasing temperature from ½= 4700 Hz (308 K, Fig. S5-
B) to ½= 2400 Hz (348 K, Figure 1A). 
 
Dissociation kinetics 
Nowadays, as far as the in vivo use of metal complexes 
concerns, there is a large consensus in saying that the kinetic 
inertness is as important as the thermodynamic stability, since 
the products of the dissociation reactions (both the free metal 
ions and ligands) could be toxic for the living systems. The 
dissociation rate of the metal ion from a GaIII complex is typically 
measured in strong acidic ([H+]>1.0 M) and basic conditions 
([OH-]>0.1 M).[7a,20,21] However, the kinetic data obtained in such 
conditions, which are considerably different from the 
physiological ones, are not fully reliable to predict the behaviour 
of GaIII complexes in body fluids. In fact, after intravenous 
administration, the GaIII-complex may also interact with the 
endogenous ions (Cu2+, Zn2+ and Ca2+) that can exchange and 
release toxic Ga3+ ion forming the corresponding metal 
complexes. 
Transmetallation reactions: To obtain information about the 
kinetic inertness of Ga(CyAAZTA)- near physiological conditions, 
we studied the kinetics of the transmetallation reactions 
occurring between the GaIII chelate and Cu2+ ions in the 
presence of citrate excess to prevent the hydrolysis of Ga3+ and 
Cu2+  ions at pH 6.0 – 9.0. Under such conditions Cu2+ is 
predominantly present as Cu(Cit)H-1 species, whereas the Ga3+ 
ion forms Ga(Cit)H-1 and Gd(Cit)2 complexes.[10,22,23] The 
absorption spectra and the species distribution of the 
Ga(CyAAZTA)- and Cu2+-citrate reacting system are presented 
in Figures 3 and S3.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Absorption spectra of Cu(CyAAZTA)2- and Ga(CyAAZTA)- - 
Cu(Citrate) reacting system as a function of time at pH=7.50. Inserted figure 
shows the absorbance values of the reacting system at 300 nm as a function 
of time  ([Ga(CyAAZTA)-] = 1.0 mM, [Cu(CyAAZTA)2-] = 0.3 mM, [Cu2+]tot=0.3 
mM, [Cit3-]tot = 2.0 mM, [HEPES] = 0.01 M, l=1 cm, 0.1 M KCl, 25C). 
The transmetallation reaction between Ga(CyAAZTA)- and Cu2+ 
is expressed by the following equation: 
 
Ga(CyAAZTA)-  +  Cu2+    Cu(CyAAZTA)2- + Ga3+      (7) 
 
The rates of the transmetallation reactions were studied in the 
presence of excess of Ga(CyAAZTA) ([GaL]tot/[Cu2+]tot = 5) when 
a pseudo-first order kinetic model can be applied and the rates 
of transmetallation can be expressed by Eq. (8): 
                                   
       
 (8) 
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where kd is a pseudo-first-order rate constant, [GaL]t and [CuL]t 
are the concentration of complexes (e.g. GaL, Ga(L)H-1, CuL, 
Cu(L)H-1), at the time t, respectively. During the progress of the 
transmetallation reactions the concentration of Cu(CyAAZTA) 
and Cu(CyAAZTA)H-1 complexes increases (the deprotonation 
of the Cu(CyAAZTA) complex takes place in the pH range 8 – 
11), while that of Cu(Cit)H-1 decreases. By the use of 1.0 cm 
cells, the first-order rate constant, kd can be expressed by Eq. 
(9): 
 
 (9) 
 
 
In the Eq. (9) Abs/t values (the increase of the absorbance 
during the time t) are calculated from the slope of the kinetic 
curves. Cu(Cit)H-1 and CuL are the molar absorptivities of the 
Cu(Cit)H-1 (921 M-1cm-1), Cu(CyAAZTA) (2435 M-1cm-1) and 
Cu(CyAAZTA)H-1 (2811 M-1cm-1) complexes at 300 nm (the 
absorption of the Ga3+ containing species at 300 nm can be 
neglected). The CuL of Cu(CyAAZTA) species at given pH can 
be expressed as a weighted average of the molar absorptivities 
of the Cu(CyAAZTA) and  Cu(CyAAZTA)H-1 complexes by 
taking into account the protonation constant of Cu(CyAAZTA)H-1 
(logKCuLH-1=9.62 (2)) determined by pH-potentiometric titration of 
the Cu(CyAAZTA) at 25C in 0.1 M KCl). The obtained pseudo-
first-order rate constants for the reaction of Ga(CyAAZTA)- with 
Cu2+ at different pH and [OH-] values in the presence of citrate 
are shown in Figure 4. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. kd values vs. pH for the reaction between Ga(CyAAZTA)- and Cu2+. 
([Ga(CyAAZTA)-] = 1.0 mM, [Cu2+]=0.2 mM [Cit]=1.0 mM (), 2.0 mM (), 3.0 
mM (), 4.0 mM (), [MES]=[HEPES] = 0.01 M, 0.1 M KCl, 25C). 
Since the reaction rate is independent from the concentration of 
citrate and Cu(Cit)H-1 (Figure 4), it can be assumed that the rate 
determining step is the dissociation of Ga(CyAAZTA)-, followed 
by the fast metal exchange reaction between Cu(Cit)H-1 species 
and the free CyAAZTA ligand. The increase of kd values with the 
increase of [OH-] (Figure 4) can be explained by the equilibrium 
formation of [Ga(CyAAZTA)OH]2- (Eq. (6)), which slowly 
dissociates in spontaneous (Eq. (10)) and OH- assisted (Eq. 
(11)) reactions.    
 
[Ga(CyAAZTA)OH]2-  Ga3+  +   HxCyAAZTA   +   OH- (10) 
 
 
[Ga(CyAAZTA)OH]2-+ OH- Ga3++ HxCyAAZTA+2OH-(11) 
 
By taking into account these two pathways, the rate of the 
transmetallation of Ga(CyAAZTA)- can be expressed by Eq. (12). 
 
 
 (12) 
 
 
Considering the total concentration of the complex ([GaL]tot = 
[GaL]+[Ga(L)OH]), the pseudo-first-order rate constant (kd) can 
be expressed as follows:   
 
   
    (13) 
 
 
where KGa(L)OH equilibrium constant, kOH and kOH2 rate constants 
characterizing the spontaneous and OH- assisted dissociation of 
[Ga(CyAAZTA)OH]2-, respectively. The rate and equilibrium 
constants characterising the transmetallation reaction of 
Ga(CyAAZTA)- in the presence of citrate were calculated by 
fitting the kd values presented in Figure 4 to the Eq. (13) and the 
values obtained are shown and compared with those of 
Ga(AAZTA)- in Table 3.  By taking into the ionic product of water 
for the related condition (pKw=13.87, 0.1 M KCl, 25C), the 
logKGaLH-1 of Ga(CyAAZTA)- can be calculated from the KGa(L)OH 
equilibrium constant obtained from the kinetic data               
(KGaLH-1=1/KwKGa(L)OH). The “deprotonation” constant (logKGaLH-1) 
obtained by pH-potentiometry (logKGaLH-1=7.31 (3)) and from the 
kinetic data (logKGaLH-1=7.34 (8)) are in very good agreement. 
 
Table 3. Rate and equilibrium constants and half-lives (t1/2=ln2/kd) for the 
transmetallation reactions of Ga(CyAAZTA)- and Ga(AAZTA)- complexes 
(0.1 M KCl, 25C) 
 Ga(CyAAZTA)- Ga(AAZTA)[a] 
kOH (s-1) (1.7  0.1)10
-5 3.010-6 
kOH2 (M-1s-1) 68  5 10 
KGa(L)OH (M-1) (3.4  0.1) ×106 1.4 ×109 
pKw[b] 13.87 
logKGaLH-1 7.34 (1) 4.72 
kd (s-1)              
at pH=7.4 2.310
-5 9.210-6 
t1/2 (h) 
at pH=7.4 8.5 21 
[a] Ref. [5], [b] determined by pH-potentiometry (0.1 M KCl, 25C) 
 
The kOH and kOH2 rate constants for [Ga(CyAAZTA)OH]2- are 6 - 
7 times higher than the corresponding rate constants of 
[Ga(AAZTA)OH]2-. The spontaneous dissociation of 
[Ga(CyAAZTA)OH]2- and [Ga(AAZTA)OH]2- likely proceeds 
through the intramolecular rearrangement of the GaIII complexes 
that results in the simultaneous de-coordination of all donor 
atoms with the consequent release of Ga3+ ion. The faster 
spontaneous dissociation of [Ga(CyAAZTA)OH]2- might be 
interpreted by the coordination of OH- to the Ga3+-ion which 
cause the weakening of the interaction between the Ga3+-ion 
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and both ring N donor atoms due to the rigidity of the CyAAZTA 
skeleton. 
With the use of the rate and equilibrium constants presented in 
Table 3, the half-lives (t1/2=ln2/kd) of the dissociation reactions of 
Ga(CyAAZTA)- and Ga(AAZTA)- can be calculated for any pH by 
Eq. (13). The t1/2 values of Ga(CyAAZTA)- and Ga(AAZTA)- 
calculated for pH=7.4 are 8.5 and 21 hours, which indicate a 
lower kinetic inertness of Ga(CyAAZTA)- due to the faster 
spontaneous dissociation of [Ga(CyAAZTA)OH]2-.  However, by 
calculating the dissociation half-lives at pH=6.0, t1/2 values of 
234 and 64 hours can be found for Ga(CyAAZTA)- and 
[Ga(AAZTA)OH]2-, respectively. These data highlight a higher 
kinetic inertness of Ga(CyAAZTA)- at lower pH due to its 
significantly higher conformational rigidity than that of 
[Ga(AAZTA)OH]2- (Ga(CyAAZTA)- is the predominant species at 
pH=6.0).  
 
Transferrin challenge reactions. Another mechanism that could 
be responsible for the dissociation of Ga(CyAAZTA)- in body 
fluids is related to the strong affinity of Ga3+ for transferrin (Ga3+-
transferrin: logKGaTf=18.88, logKGa2Tf=17.65).[24] Because of the 
relatively high concentration of the transferrin in human 
plasma,[25] this protein could compete with CyAAZTA for the 
Ga3+ ion leading to the significant dissociation of Ga(CyAAZTA)-. 
In order to determine the extent of the competition between 
CyAAZTA and transferrin, the ligand exchange reaction between 
Ga(CyAAZTA)- and human serum transferrin (sTr) was followed 
by spectrophotometry at the absorption band of the Ga3+-sTf 
complex in the 240 - 250 nm range (Figure 5). The absorbance 
values of Ga(CyAAZTA)- - sTf reacting systems obtained at 
[sTf]=10 and 15 M are shown in Figure S6. The ligand 
exchange reaction between Ga(CyAAZTA)- and human sTf is 
expressed by the following equation: 
 
Ga(CyAAZTA)-   +   sTf          Ga(sTf)  +   CyAAZTA     (14) 
 
The rates of the ligand exchange reaction were studied at 
different concentrations of the exchanging human transferrin 
([sTf]=10 and 15 M) in the presence of high excess of 
Ga(CyAAZTA)- ([Ga(CyAAZTA)]=0.1 mM). At such condition, the 
ligand exchange reaction can be treated as a pseudo-first-order 
process and the rate of the reactions can be expressed with the 
Eq. (8). By taking into account the molar absorptivity of Ga(sTf) 
(246=13800 cm-1M-1),[10] the rate constants (kd) were calculated 
from the slope of the kinetic curves (Abs/t, Figure S6) with Eq. 
(9) (the middle term of Eq. (9) has been replaced by 1/Ga(sTf)).  
The slope of the kinetic curves are considered up to 40% 
conversion in order to be sure of the Ga(sTf) complex formation. 
The rate constants (kd) obtained at 10 and 15 M human sTf 
concentration were 2.810-5 and 3.010-5 s-1, respectively 
(average value 2.9 10-5 s-1). 
The kd rate constants characterizing the ligand exchange 
reaction of Ga(CyAAZTA)- with sTf (kd=2.910-5 s-1) and the 
metal exchange reaction between Ga(CyAAZTA)- and Cu2+ in 
the presence of citrate (kd=2.310-5 s-1) at pH=7.4 and 25C in 
0.1 M KCl are essentially equal. These findings suggest that 
human transferrin has no effect on the rate of dissociation, which 
practically takes place through the spontaneous and hydroxide 
assisted dissociation of [Ga(CyAAZTA)OH]2- followed by the fast 
reaction between the released Ga3+ ion and human sTf at 
physiological condition.  
In conclusions, the dissociation half-life values of Ga(CyAAZTA)- 
calculated from the transmetallation studies (t1/2=8.5 h) and from 
the ligand exchange reactions (t1/2=6.6 h) indicates that the 
kinetic inertness of Ga(CyAAZTA)- at physiological conditions is 
7 times higher than the half-life of the radioactive decay of 68Ga 
isotope (t1/2=67.71 min). On the basis of these results the 
Ga(CyAAZTA) could represent a good candidate for the 
development of the Ga3+-based radiodiagnostics. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Absorption spectra of the Ga(CyAAZTA)- - transferrin system. 
Inserted figure shows the absorbance values of the reacting system at 246 nm 
as a function of time  ([GaL] = 0.1 mM, [Trf] = 10 M, [NaHCO3]=25 mM, pH = 
7.4, 0.15 M NaCl, 25C). 
68Ga labelling. AAZTA is a pseudo-macrocyclic chelator which 
has the advantages of either fast complexation kinetics typical of 
the open chain ligands and of forming stable chelates typical of 
macrocyclic ones.[10] AAZTA was shown to form the 68Ga-
labelled complex at room temperature and pH 3.8 (acetate 
buffer).[11] These experimental conditions were used for the 68Ga-
labelling of a 10 M solution of CyAAZTA (25 °C, 0.25 M acetate 
buffer pH 3.8, 15 min, 15-20 MBq of 68Ga). A labelling yield of 
80.7 ± 0.8 % was measured by radio-TLC, demonstrating the 
excellent efficiency of the novel chelate for 68Ga incorporation at 
room temperature. HPLC analysis of the radiolabelled complex 
showed the formation of a single species (Figure 6a), differently 
from what observed earlier in case of 68GaAAZTA.[12a] Since the 
use of an appropriate buffer during the radiolabelling step is 
essential to maximize the labelling yield and the specific 
activity,[26] 4-(2-hydroxyethyl)piperazine-1-ethanesulfonic acid 
(HEPES) buffer was also selected, due to its widely usage for 
68Ga labelling, as it has a weak metal complexing capacity to 
avoid the formation of colloidal gallium. In spite of the favourable 
expectations, the labelling using HEPES at pH 3.8 (0.2 M) and 
25°C for 15 min gave unsatisfactorily results (L.Y.: 53 ± 3%, 10 
µM) with respect to acetate buffer. The 68Ga labelling of 
CyAAZTA at different temperatures (25, 37 and 90 °C) and at 
different ligand concentrations (0.5-100 M) was tested (Figure 
6b). A labelling yield > 80% was found at room temperature for 
concentrations higher than 10 M whereas at lower 
concentrations the labelling efficiency decreased. The labelling 
at 37°C only slightly increased the yield for each concentration; 
in particular, 85.8 ± 0.9 % yield could be obtained for 10 M 
ligand concentration. For 1 M CyAAZTA concentration (2.4 
nmol), the labelling efficiency could be improved by increasing 
the temperature to 90°C. In fact, a radiochemical incorporation 
of 96.9% was accomplished after 5 min heating.  Similar results 
were obtained for higher concentrations of the chelator whereas 
the further decrease of the ligand concentration to 0.5 M did 
not yield a successful incorporation of the radiometal. The fast 
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and nearly quantitative labelling at 90°C may result in higher 
specific activity of CyAAZTA-conjugated peptide or peptide-
mimetics that is essential for an accurate quantification of PET 
examinations. The kinetics of 68Ga incorporation for 1 M 
CyAAZTA concentration in acetate buffer (pH 3.8) at 25 and 
37°C was also studied (Figure 6c). The data show a slightly 
faster complexation kinetic at higher temperatures and confirm 
that the 68Ga labelling of CyAAZTA can be efficiently carried out 
either at room or physiological temperature. Therefore, this 
chelator is suitable for conjugation to temperature labile vectors 
such as antibody derived fragments (Fab, diabodies, 
nanobodies, affibodies)[27,28] or antibody-like molecules 
(anticalins).[27] This claim prompts by considering that AAZTA 
was modified in several ways in order to conjugate it to 
biomolecules, i.e. bifunctional AAZTA chelators bearing 
amino,[9c] isothiocyanate,[9c] carboxylate[29] or hydroxyl[9b] groups 
have been reported in the literature. Thus, also CyAAZTA can 
be functionalized with the same reactive groups using analogous 
procedures. 
Finally, although kinetic studies and transferrin challenge 
reactions on GaCyAAZTA were discussed in detail previously, 
the relative stability of the radiolabelled complex was also 
assessed to confirm the data reported for the cold chelate. 
68GaCyAAZTA (10 µM, formed at 90 °C, 0.25 M acetate buffer 
pH 3.8, 5 min, 15-20 MBq of 68Ga) was diluted in the presence 
of an excess DTPA and in human serum and its stability was 
checked by HPLC and radio-TLC as a function of time at 37°C 
(Figure S7). No transmetallation reaction over 90 min was 
measured. Noteworthy, the reported data on 68Ga CyAAZTA 
labelling and stability compare favourably with the behaviour 
described for related acyclic and macrocyclic ligands.[1,2,6-8] 
Conclusions 
The presence of the trans-1,2-diaminocyclohexyl group in the 
newly synthesized ligand CyAAZTA led to the formation of a 
structurally rigid GaIII complex having good thermodynamic 
stability. The kinetic inertness of Ga(CyAAZTA)- was determined 
via transmetallation and ligand exchange reactions with Cu2+ 
ions and transferrin, respectively, showing a slight tendency to 
decomplex the Ga3+ ion through the formation of the hydroxo-
complex at physiological pH. Remarkably, the kinetic data 
obtained in such conditions appear more reliable to predict the 
behaviour of GaIII complexes in body fluids than those typically 
used in the literature, i.e. dissociation rate of the metal ion 
measured in strong acidic and basic conditions. The 
thermodynamic stability and kinetic inertness of Ga(CyAAZTA)- 
is well suitable for 68Ga PET studies as it is considerably longer 
than the radioactive half-life of the 68Ga isotope. The 
complexation of 68Ga with CyAAZTA was observed at RT and 
pH 3.8 within 15 min with the yield of >80% and at 90°C with 
almost quantitative yield (in 5 min). 68GaCyAAZTA was 
confirmed to be stable in human plasma and in excess of DTPA 
at 37 °C. The potential of the proposed chelator is strenghtened 
by the wide spectrum of possible bifunctional chelators that can 
be prepared adapting to CyAAZTA the procedures used for the 
synthesis of functionalized AAZTA ligands. Therefore, whereas 
the labelling at room temperature can be of interest for 
temperature sensitive molecules, labelling at higher 
temperatures may be advantageous for reaching higher specific 
activity in peptide radiopharmaceuticals. 
 
 
Figure 6. a) Radio-HPLC analysis of 68GaCyAAZTA; b) Radiochemical yield (68Ga incorporation) as a function of CyAAZTA concentration (0.5, 1, 5, 10 and 100 
M) at 25°C (■), 37°C (○) and 90°C (◊) (15-20 MBq in 500 L, pH 3.8 acetate buffer); c) Time course of 68Ga complexation reaction at 25°C and 37°C for 1 M 
CyAAZTA concentration. 
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Experimental Section 
General All reagents and solvents were obtained from commercial 
suppliers and directly used without further purification. The NMR spectra 
were recorded on Bruker Avance III (11.74) instruments. Chemical shifts 
are reported in δ relative to an internal standard of residual solvent. 
Electrospray ionization mass spectra (ESI MS) were recorded on a SQD 
3100 Mass Detector (Waters), operating in positive or negative ion mode, 
with 1% v/v formic acid in methanol as the carrier solvent. 1.0 M HCl for 
elution of 68Ge/68Ga generator was prepared from HCl (Suprapur®) and 
water (Ultrapur®), both obtained from Merck. Ultrapur® water was also 
used for all radiochemical works, including the preparation of precursors 
and buffers solutions. 2-[4-(2-Hydroxyethyl)-1-piperazinyl]-ethanesulfonic 
acid (HEPES) was obtained from Merck and sodium acetate from Sigma. 
Radio-TLC was performed on Varian glass microfiber chromatography 
papers impregnated with silicic acid (#A120B12). Readout of TLC 
chromatograms was done using a Bioscan TLC scanner, consisting of B-
MS-1000 scanner, B-EC-1000 detector with a B-FC-3600 GM tube. 
Analytical HPLC was performed using a Shimazu HPLC System with low 
pressure gradient unit, equipped with a Nucleosil C18-RP column 
(250x4.6 mm, 5 µm particle size) from Machery-Nagel, at flow rate of 1 
ml/min, and a SPD 20A Variable Wavelength Detector (UV/VIS) set at 
254 nm. Eluent were water and acetonitrile, both containing 0.1 % 
trifluoroacetic acid (TFA).  
Materials Ga(NO3)3 was prepared by dissolving Ga2O3 (99.9%, Fluka) in 
6M HNO3 and evaporating of the excess acid. The solid Ga(NO3)3 was 
dissolved in 0.1 M HNO3 solution.  The concentration of the Ga(NO3)3 
solution was determined by using the standardized Na2H2EDTA in 
excess. The excess of the Na2H2EDTA was measured with standardized 
ZnCl2 solution and xylenol orange as indicator. The concentration ZnCl2 
(Sigma) and CuCl2 (Sigma) solutions were determined by 
complexometric titration with standardized Na2H2EDTA and xylenol 
orange (ZnCl2) and murexide (CuCl2) as indicator. The H+ concentration 
of the Ga(NO3)3 solution was determined by pH potentiometric titration in 
the presence of excess Na2H2EDTA. The concentration of H4CyAAZTA 
was determined by pH-potentiometric titrations in the presence and 
absence of a 40-fold excess of Ca2+. The citrate solution was prepared 
from H3Citrate (Sigma) and its concentration was determined by pH-
potentiometry. The pH-potentiometric titrations were made with 
standardized 0.2 M KOH.  
Synthesis of (±) trans-1,2-dibenzylaminocyclohexane diacetate (1) 
Benzaldehyde (2.26 mL, 22.4 mmol) was dropped to a suspension of (±) 
trans-1,2-diaminocyclohexane (1.16 g, 10.2 mmol) and a small amount of 
MgSO4 (ca. 200 mg) in 10 mL of DCM. NaBH4 (1.54 g, 40.7 mmol) was 
slowly added to the mixture which was then stirred vigorously at room 
temperature. After 18 h the mixture was washed with water (3 x 10 mL). 
The organic phase was then dried over Na2SO4, acidified with acetic acid 
(1.5 mL) and evaporated to obtain an oil that was further washed with 
hexane (3 x 10 mL) to remove unreacted benzaldehyde. (±) trans-1,2-
dibenzylaminocyclohexane diacetate (1) was obtained as a yellow oil 
after drying under vacuum (3.15 g, 7.6 mmol, 74.5% yield). 1H-NMR 
CDCl3 400 MHz:  1.75 (m, CH2, 4H), 2.11 (m, CH2, 4H), 3.60 (s, CH2, 
4H), 7.22-7.37 (m, CHPh, 10H); 13C-NMR CDCl3 100 MHz:  1.75  23.1 
(CH2), 31.1 (CH2), 56.4 (CH2), 71.4 (CH2), 128-130 (CHPh). ESI+-MS: 
295.45 [M+H+], MW calc. for C20H26N2 = 294.43. 
Synthesis of trans-1,5-dibenzyl-3-methyl-3-nitrodecahydro-1H-1,5-
benzodiazepine (2) Paraformaldehyde (250 mg, 8.3 mmol) and 
nitroethane (178.7 mg, 2.38 mmol) were added to a solution of (±) trans-
1,2-dibenzylaminocyclohexane diacetate (987 mg, 2.38 mmol) in 100 mL 
of a mixture of EtOH and Toluene (1:1 v/v). The mixture was then heated 
to reflux and stirred overnight. The evaporation of the solvent gave 1.5 g 
of crude product which was purified by column chromatography (silica gel, 
eluents: 9:1 Petrol Ether/Ethyl acetate, Rf = 0.56) to obtain 2 as a pale 
yellow oil (0.55 g; 1,4 mmol, 59% yield). 1H-NMR  CDCl3 500 MHz: 1.03 
(d q, CH2, 2H), 1.28 (b , CH2, 4H), 1.34 (s, CH3, 3H), 1.76 (m, CH2, 2H), 
1.85 (b, CH2, 1H), 2.11 (d, CH2, 1H), 2.46 (t, CH, 1H), 2.69 (b, CH2, 1H), 
2.87 (d, CH2, 1H), 3.35 (d, CH2, 1H), 3.55 (d, CH2, 1H), 3.64 (d, CH2, 1H), 
3.87 (d, CH2, 1H), 3.98 (d, CH2, 1H), 4.11 (d, CH2, 1H), 4.17 (s, CH2, 1H), 
7.28-7.36 (m, CHAr, 10H); 13C-NMR CDCl3 125 MHz: CH3), 24.6 
(CH2), 25.1 (CH2), 26.4 (CH2), 31.9 (CH2), 51.1 (CH2), 56.5 (CH2), 56.6 
(CH2), 58.9 (CH2), 60.4(CH), 66.4 (CH), 93.2 (C), 127-129 (5 CHAr), 
139.1 (CAr). ESI+-MS: 394.36 [M+H+], MW calc. for C24H31N3O2 = 393.24. 
Synthesis of trans-3-amino-3-methyldecahydro-1H-1,5-benzodiazepine 
(3) Compound 2 (0.55 g, 1.4 mmol) was dissolved in MeOH (10 mL) and 
acetic acid (160 uL, 2.8 mmol). After addition of Pd/C (26 mg, 10% w/w), 
the reaction was carried out under H2 pressure (5 Bar) and vigorous 
stirring at room temperature overnight (18h). The catalyst was removed 
by filtration and the methanol was removed to obtain 410 mg of the 
amine 3 as diacetate salt (96% yield). 1H-NMR  MeOD 500 MHz:  1.19 
(m, CH2, 4H), 1.38 (s, CH3, 3H), 1.79 (b. CH2, 4H), 2.0 (s, NH, 2H), 2.64 
(b, CH2, 2H), 2.86 (b, CH2, 2H), 3.11 (m, CH, 1H), 3.33 (m, CH, 1H); 13C-
NMR CDCl3 125 MHz: 22.3 (CH3), 24.2 (CH2), 31.5 (CH2), 54.8 (C), 
56.9 (CH2), 66.9 (CH); ESI+-MS: 184.18 [M+H+], MW calc. for C10H21N3 = 
183.29. 
Synthesis of trans-1,5-bis(t-butoxycarbonylmethyl)-3-[bis(t-
butoxycarbonylmethyl)]amino-3-methyldecahydro-1H-1,5benzodiazepine 
(CyAAZTA tetra-t-butylester, 4) tert-butilbromoacetate (473 L, 3.2 mmol) 
was added to a suspension of compound 3 (120 mg, 0.40 mmol) and 
K2CO3 (550 mg, 4 mmol) in 10 mL of acetonitrile.  The mixture was 
stirred at 80°C overnight. After then it was filtered and the solvent was 
evaporated to obtain an orange oil. After purification by column 
chromatography (silica gel, eluents: 9:1 Petrol Ether/Ethyl acetate, Rf = 
0.55), 4 was obtained as a pale yellow oil (140 mg, 0.22 mmol, 55% 
yield). 1H-NMR  CDCl3 500 MHz: 1.08-1.13 (b, CH2, 4H), 1.37 (s, tBu 
CH3, 36H), 1.42 (b, CH3, 3H), 1.64 (b, CH2, 4H), 2.39-2.47 (b, CH2, 4H), 
2.80-2.98 (m, CH, 2H), 3.4-3.5 (m, CH2, 8H); 13C-NMR CDCl3 125 MHz: 
14.2 (CH3), 22.6 (CH2), 25.7 (CH2), 28.2 (CH3tBu), 51.4 (CH2), 60.3 
(CH2), 61.9 (CH), 69.4 (C), 80.5 (CtBu), 172.7 (C=O); ESI+-MS: 640.45 
[M+H+], MW calc. for C34H61N3O8 = 639.86. 
Synthesis of trans-3-amino-3-methyldecahydro-1H-1,5-benzodiazepine-
N,N',N",N"tetraacetic acid (CyAAZTA) Compound 4 (140 mg, 0.22 mmol) 
was dissolved in 2 mL of DCM. Trifluoroacetic acid (2 mL) was then 
added and the solution was stirred overnight at room temperature. After 
evaporation of the solvent, the solid was washed three times with diethyl 
ether (5 mL) and then dried under vacuum to obtain the ligand L as the 
mono-trifluoroacetic salt (101 mg, 0.19 mmol, 87% yield). The solid was 
then dissolved in 2-3 mL of water and the pH was raised to 6.5 by 
addition of a few drops of a 1 M solution of NaOH and then lyophilized. 
1H-NMR  D2O 500 MHz:  1.23 (s, CH3, 3H), 1.25 (m, CH2, 2H), 1.38-
1.44 (m, CH2, 2H), 1.75 (m, CH2, 2H), 1.98 (m, CH2, 2H), 3.12-3.20 (m, 
CH, 2H), 3.36-3.62 (m, CH2, 4H), 3.72-3.79 (m, CH2, 8H); 13C-NMR D2O 
125 MHz: 14.1 (CH3), 24.2 (CH2), 26.6 (CH2), 48.0, 51.0, 53.6, 54.7 
(CH2), 64.2 (CH), 66.2 (C), 170.0, 173.5 (C=O); ESI+-MS: 416.4 [M+H+], 
MW calc. for C18H30N3O8 = 416.44. 
Equilibrium measurements The stability and protonation constants of 
Ga(CyAAZTA)- were determined by pH-potentiometric titration from 
acidic to basic pH range by studying the competition reaction between 
CyAAZTA and OH- for Ga3+ ([CyAAZTA]=[Ga3+]= 310-3 M). The 
protonation constants of Cu(CyAAZTA)2- were determined by pH-
potentiometric titrations of CuL complex in the pH range of 1.7 – 11.7 
([Cu(CyAAZTA)]= 310-3 M). For pH measurements and pH-
potentiometric titrations, a Metrohm 785 DMP Titrino titration workstation 
and a Metrohm-6.0233.100 combined electrode were used. Equilibrium 
measurements were carried out with 120 s waiting time between two pH-
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KOH datapairs at a constant ionic strength (0.1 M KCl) in 6 ml samples at 
25 C. The solutions were stirred, and N2 was bubbled through them. The 
titrations were made in the pH range of 1.7-11.7. KH-phthalate 
(pH=4.005) and borax (pH=9.177) buffers were used to calibrate the pH 
meter. For the calculation of [H+] from the measured pH values, the 
method proposed by Irving et al. was used. A 0.01M HCl solution was 
titrated with the standardized KOH solution in the presence of 0.1 M KCl 
ionic strength. The differences between the measured (pHread) and 
calculated pH (-log[H+]) values were used to obtain the  equilibrium H+ 
concentration from the pH values, measured in the titration experiments. 
The ionic product of water (pKw) at 25C in 0.1 M KCI was found to be 
13.87.[30] The stability constant of Cu(CyAAZTA)2- was determined by 
spectrophotometry in the [H+] range of 0.01 – 1.0 M ([CyAAZTA]=[Cu2+]= 
210-3 M). Seven samples were prepared for determination and the H+ 
concentration ([H+]=0.010, 0.025, 0.050, 0.10, 0.30, 0.50 and 1.0 M) in 
the samples was adjusted with the addition of calculated amounts of 2.0 
M HCl. The samples were kept at 25 C for 7 days in order to attain the 
equilibrium (the time needed to reach the equilibria was determined by 
spectrophotometry). The absorbance values of the samples were 
measured at 11 wavelengths (575, 595, 615, 635, 655, 675, 695, 715, 
735, 755 and 775 nm). The ionic strength of samples with [H+]=0.30, 0.50 
and 1.0 M was not constant (the ionic strength of samples with 
[H+]=0.010, 0.025, 0.050, 0.10 M was [H+]+[K+]=0.1 M). For the 
equilibrium calculations, the molar absorptivities of the Cu2+, 
Cu(CyAAZTA), Cu(HCyAAZTA)-, Cu(H2CyAAZTA), Cu(H3CyAAZTA)+ 
and Cu(CyAAZTA)H-1 were used. The molar absorptivities of Cu2+ and 
Cu(CyAAZTA)2- complexes were determined by recording the VIS 
spectra (=400 – 800 nm) of 1.010-4, 2.010-4, 3.010-4 and 4.010-4 M 
solutions in the pH range 1.7 – 11.7 (0.1 M KCl, 25C). The pH was 
adjusted by stepwise addition of concentrated KOH or HCl. The 
spectrophotometric measurements were made with the use of a Cary 1E 
spectrophotometer at 25 C, using 1.0 cm cells. The protonation and 
stability constants were calculated with the PSEQUAD program.[31] 
NMR experiments 1H- and 71Ga-NMR measurement were performed with 
a Bruker DRX 400 (9.4 T) equipped with a Bruker VT-1000 
thermocontroller and a BB inverse z gradient probe (5 mm). The 
formation and protonation/deprotonation processes of the Ga(CyAAZTA) 
were followed from acidic to basic pH range at 298K in 0.1 M KCl. For 
these experiments, 0.015 M solution of the Ga(CyAAZTA) in H2O was 
prepared (a capillary with D2O was used for lock). The pH was adjusted 
with the addition of the concentrated solution of KOH and HCl. Because 
of the metal exchange between the Ga(CyAAZTA)OH and [Ga(OH)4]- 
was in the “slow exchange regime” on the actual NMR timescale, the 
calculation of the logGaLH-1 value of Ga(CyAAZTA)OH was performed by 
using the integrals of the 71Ga-NMR signal of [Ga(OH)4]- complex. The 
molar integral values of 71Ga-NMR signal of [Ga(OH)4]- complex were 
determined by recording the 71Ga NMR spectra of 0.01, 0.015, 0.02 and 
0.025 M solutions of [Ga(OH)4]- complex (pH=12.5, 0.1 M KCl, 25C).   
Transmetallation kinetic The rates of the exchange reactions taking place 
between Ga(CyAAZTA) and Cu2+ in the presence of citrate were studied 
by spectrophotometry, following the formation of the Cu(CyAAZTA) or 
Cu(CyAAZTA)H-1 complexes at 300 nm, with the use of 1.0 cm cells and 
a Cary 1E spectrophotometer. The concentration of Cu2+ was 0.2 mM, 
while that of Ga(CyAAZTA) was 5 times higher, in order to ensure 
pseudo-first-order conditions. In order to prevent the hydrolysis of Ga3+ 
and Cu2+  ions, the transmetallation reactions were studied in the 
presence of citrate excess ([Cit]t=1.0 – 4.0 mM).  The exchange rates 
were studied in the pH range about 6.0 - 9.0. For keeping the pH values 
constant, MES (pH range 6.0 - 7.0), HEPES (pH range 7.0 - 8.5) and 
piperazine (pH range 8.5 - 9.0) buffers (0.01 M) were used. The 
temperature was maintained at 25C and the ionic strength of the 
solutions was kept constant (0.1 M KCl). The formation rates of 
Cu(CyAAZTA) or Cu(CyAAZTA)H-1 were determined by the initial rate 
method. The pseudo-first-order rate constants (kd) were calculated from 
the tangent to the absorbance vs. time curves (Abs/t) with Eq. (9). For 
the calculations, the molar absorptivities of Cu(CyAAZTA)2-, 
Cu(CyAAZTA)H-1 and Cu(Cit)H-1 were used, which were determined at 
300 nm by recording the spectra of 1.010-4, 2.010-4, 3.010-4 and 
4.010-4 M solutions in the pH range 5 - 10 (0.1 M KCl, 25C). The 
calculations were performed with the use of the computer program 
Micromath Scientist, version 2.0 (Salt Lake City, UT, USA). 
Ligand-exchange kinetics with transferrin The ligand exchange reaction 
between Ga(CyAAZTA)- and human serum transferrin (Sigma, partially 
Fe3+ saturated) have been studied by spectrophotometry, following the 
formation of Ga(sTf) complex at 246 nm and pH=7.4 with the use of 1.0 
cm cells and Cary 1E spectrophotometer. The concentration of the 
human serum transferrin solution was determined from the aborbance at 
280 nm using the molar absorptivity 280=91200 cm-1M-1.[32] In order to 
ensure the pseudo-first-order condition, the rate of the ligand exchange 
reactions were studied in the presence of high excess of Ga(CyAAZTA)- 
([Ga(CyAAZTA)]=0.1 mM, [sTf]=10 and 15 M)). The temperature was 
maintained at 25C, the ionic strength and the hydrogen-carbonate 
concentration of the samples were kept constant; 0.15 M for NaCl and 
0.025 M for NaHCO3, respectively.   
68Gallium labelling Manual synthesis was used for investigation of 
radiolabeling properties, namely buffer, concentration and time 
dependencies of radioactivity incorporation. A 68Ge/68Ga-generator with 
SnO2 matrix (obtained from ITHEMBA LABS, South Africa) was eluted 
with 1.0 M aq. HCl. To a fraction of 1.20 mL containing the highest 
activity (ca. 700 MBq). For buffer dependency 68Ga incorporation study, a 
solution of HEPES (0.2 M, 800 µL) or sodium acetate (0.25 M, 500 µL 
plus 300 µL of 1.0 M aq. HCl) was added to the eluate and mixed by brief 
shaking, resulting in 2.0 mL solution at pH 3.8. Of this solution, 50 μL 
aliquots were transferred into eppendorf vials containing 450 μL volume 
of stock solutions of CyAAZTA ligand with appropriate concentrations 
(ranging from 0.1x10–3 to 0.5×10–6 M), resulting in 500 μL reaction 
solutions. Heating (when applied) was performed by placing the closed 
eppendorf vials into a thermostated water bath. After heating, labeling 
reactions were interrupted by placing the cups into a cold water bath. 
Radioactivity incorporation was determined by radio-TLC, while samples 
were withdrawn after completed cooling or, in case of reactions at 25 °C, 
during the reaction at several time points, for kinetic of incorporation 
studies. 
Quality control Radio-TLC of the product was performed on VARIAN 
glass microfiber chromatography papers impregnated with silicic acid (cat. 
#A120B12), using two different solvents. TLC-A:  0.1 M aq. sodium 
citrate as mobile phase, where free 68Ga3+ is eluted with the solvent front 
as citrate complex (RF = 0.8–1) and the product stays at the origin (RF = 
0). TLC-B: 1.0 M NH4OAc/MeOH (1:1) as mobile phase, where insoluble 
colloidal 68GaIII stays at the origin (RF = 0) and the radiolabeled product is 
eluted with the solvent front (RF = 0.5-0.6). Radio-TLCs were evaluated 
using a BIOSCAN TLC scanner consisting of B-MS-1000 scanner, B-EC-
1000 detector with a B-FC-3600 GM tube. Radio-HPLC was performed 
on a Shimazu system using a Nucleosil C18-RP column (MAchery-Nagel, 
250×4.6 mm) with radioactivity and UV detection (254 nm). Eluents were 
water (A) and acetonitrile (B), both containing 0.1 % TFA (flow rate 1 
mL/min, isocratic elution with a gradient  from 15 % B to 20 % B in 10 
min and isocratic elution with 90 % B for 5 min). Retention time of 
CyAAZTA ligand 10 µM radiolabeled at 25 and 37 °C, and CyAAZTA 
ligand 1 µM radiolabeled at 90 °C was invariably 4.4 min (activity 
channel). Radiochemical purity was of 68Ga-CyAAZTA was >98.0 % 
determined by radio-HPLC, and > 97.0 % determined by radio-TLC.  
Stability tests Stability of the 68Ga-CyAAZTA was tested by adding 100 
µL of the product to 900 µL of human serum freshly prepared and 900 µL 
of 50 mM DTPA solution, followed by incubation at 37 °C for 90 min. 
Stability of 68GaCyAAZTA complex was determined with radio-TLC, by 
withdrawing samples (2.5 µL) during the reaction at 30, 60 and 90 min 
and spotting onto the TLC strip, and with radio-HPLC by injecting 50 µL 
of the 68Ga-CyAAZTA/50mM DTPA reaction solution at 30, 60 and 90 
min.  
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